Literature DB >> 10842697

AL amyloidosis: the last 30 years.

M Skinner1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10842697     DOI: 10.3109/13506120009146816

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


× No keyword cloud information.
  5 in total

1.  High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.

Authors:  Sumit Madan; Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; David Dingli; S Vincent Rajkumar; William J Hogan; Nelson Leung; Martha Grogan; Morie A Gertz
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

2.  Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

Authors:  Anita D'Souza; Angela Dispenzieri; Baldeep Wirk; Mei-Jie Zhang; Jiaxing Huang; Morie A Gertz; Robert A Kyle; Shaji Kumar; Raymond L Comenzo; Robert Peter Gale; Hillard M Lazarus; Bipin N Savani; Robert F Cornell; Brendan M Weiss; Dan T Vogl; César O Freytes; Emma C Scott; Heather J Landau; Jan S Moreb; Luciano J Costa; Muthalagu Ramanathan; Natalie S Callander; Rammurti T Kamble; Richard F Olsson; Siddhartha Ganguly; Taiga Nishihori; Tamila L Kindwall-Keller; William A Wood; Tomer M Mark; Parameswaran Hari
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

3.  Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.

Authors:  Shaji K Kumar; Suzanne R Hayman; Francis K Buadi; Vivek Roy; Martha Q Lacy; Morie A Gertz; Jacob Allred; Kristina M Laumann; Leif P Bergsagel; David Dingli; Joseph R Mikhael; Craig B Reeder; A Keith Stewart; Steven R Zeldenrust; Philip R Greipp; John A Lust; Rafael Fonseca; Stephen J Russell; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Blood       Date:  2012-04-13       Impact factor: 22.113

4.  Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.

Authors:  Shaji K Kumar; Morie A Gertz; Martha Q Lacy; David Dingli; Suzanne R Hayman; Francis K Buadi; Kristen Short-Detweiler; Steven R Zeldenrust; Nelson Leung; Philip R Greipp; John A Lust; Stephen J Russell; Robert A Kyle; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Mayo Clin Proc       Date:  2011-01       Impact factor: 7.616

5.  Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

Authors:  Joseph R Mikhael; Steven R Schuster; Victor H Jimenez-Zepeda; Nancy Bello; Jacy Spong; Craig B Reeder; A Keith Stewart; P Leif Bergsagel; Rafael Fonseca
Journal:  Blood       Date:  2012-02-13       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.